

Supplementary Table S4. Correlation of the expression of hPG versus ANXA2, hPG versus the CD163/HLA-DR ratio and ANXA2 versus the CD163/HLA-DR ratio in the primary tumors (T) or the lymph node metastases (LN)

| Correlation | rho | p-value |
|----------------------------------|--------|---------|
| hPG (T) vs. ANXA2 (T) | 0.437 | <.001 |
| hPG (T) vs. CD163/HLA-DR (T) | -0.125 | .343 |
| ANXA2 (T) vs. CD163/HLA-DR (T) | -0.269 | .038 |
| hPG (LN) vs. ANXA2 (LN) | 0.080 | .610 |
| hPG (LN) vs. CD163/HLA-DR (LN) | -0.012 | .939 |
| ANXA2 (LN) vs. CD163/HLA-DR (LN) | 0.045 | .776 |

hPG, progastrin; ANXA2, annexin A2; HLA-DR, human leukocyte antigen-DR.